Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (706)	1/28/2005 10:21:32 PM
From: Jibacoa	Respond to of 3722

Wayne Re: PARS It seems to be holding after its big down-gap on Dec.20 As you know,that was after it announced that its PIII of dexanabinol for brain trauma didn't show any statistical benefit. Since then the stock has managed to stay above that day's intra-day L ($0.92) Today's L even after the several announced legal "class actions" against the company, the intra-day L was $0.99 and the price increased to $1.02 after hours.<g> Since they sold their ophthalmic product line in 2001,their main expectations were centered on dexanabinol.The insiders apparently were not expecting good results since they were selling in Nov.<g> The company has had no revenues and its loss in the last 9 months has increased 32% to $17.2M. It reportedly has around $0.50 in cash/share and a Debt/Equity ratio of 0.18 Insiders hold around 3% and the short position has been cut in half since the down-gap.<g> The Dec.20 gap was from $3.60 to $1.25 (Gap=2.35) so if it can close half the gap that would be almost 100% from present levels.<g> The estimated loss for the year is $0.23 and if correct the Dec.loss would be less than the $0.07 loss in 2003.The EL for 2005 is around $0.16 Bottom line: It remains a highly speculative position at present, but if it can hold the $1 level the R/R is not too bad.<g> bigcharts.marketwatch.com RAGL Bernard